Tricol Biomedical

5 articles about Tricol Biomedical

• Tricol Biomedical Expands IP Protection with First New Patent for Gastrointestinal Hemostasis

  2/21/2023

  The US Patent and Trademark Office has granted Tricol Biomedical, a global leader in innovating hemostasis and wound care solutions, a new patent (#11,564,673) for the company’s modified chitosan dressing and its through-the-scope delivery in the gastrointestinal (GI) tract to quickly control serious bleeding for up to 96 hours.

• Tricol Biomedical Expands Product Lines with Group Purchasing Organizations Premier and Vizient; Salvin Dental Specialties Is Now Tricol’s Exclusive U.S. Dental Distributor

  12/13/2022

  Tricol Biomedical, a global leader in innovating hemostasis and wound care solutions, has expanded its GPO agreements with Premier, Inc. and Vizient® to include the OneStop™ Vascular line of procedural care products.

• Preclinical Evaluation of Tricol Biomedical’s Absorbable Biocompatible Chitosan (ABC) Wound Dressing Demonstrates Bioabsorption and Biocompatability in Internal Bleeding

  9/29/2022

  A preclinical study presented at the Military Health System Research Symposium this month demonstrated that the proprietary† Absorbable Biocompatible Chitosan investigational product from Tricol Biomedical is both absorbable and biocompatible in an internal bleeding rodent model.

• Medline Expanding Clinician Access to Products Designed to Safely Control Bleeding

  1/6/2021

  Medline and Tricol Biomedical, Inc. announced an exclusive agreement to distribute Hemostatic Control products in North America to acute care, emergency services, and cath lab providers.

• Tricol Biomedical Announces New Website Launch And Corporate Rebrand

  11/30/2016